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The mutations of the RET proto-oncogene contributes to the development of MTC by increasing the activity of the
receptor encoded by this gene. Variant T of polymorphism rs2435357 located in the enhancer of the RET gene
reduces the enhancer’s activity. The opposite effects of rs2435357 and the mutations causing medullary thyroid
carcinoma resulted in the investigation of the status of this polymorphism in patients with MTC. In our study, we
compared the frequency of polymorphism rs2435357 in the group of 48 MTC patients with its frequency in Polish
population. The frequency of heterozygotes C/T at rs2435357 reached almost 12% (18/152) for the Polish
population, in contrast to the group of MTC patients where not even a single T allele was found. The frequency
difference is statistically significant. This observation might indicate that the presence of the heterozygous T allele at
rs2435357 may be associated with the inhibition of medullary thyroid carcinoma development.Background
The RET proto-oncogene (MIM 164 761), located on
10q11.21, encodes a receptor tyrosine kinase. At the
end of the 90s, the association of RET gene mutations
with the occurrence of medullary thyroid carcinoma
(MTC) and Multiple endocrine neoplasia type 2A
(MEN 2A) was described [1,2]. Mutations in the RET
proto-oncogene, leading to the development of MTC,
increase the activity of the receptor encoded by this
gene. These mutations occur in the part of gene
encompassing exons from 11 to 16, and 75–80% of all
cases of hereditary MTC carry a mutation in codon
634 located in exon 11 [3].
The common polymorphism rs2435357 (previously
termed RET+3:C/T, with an ancestral allele C and a
derived mutation allele T) in the noncoding enhancer
element MCS+9.7 (Multispecies Conserved Sequence
located 9.7 kb from the ATG codon) in intron 1 of
the RET gene is a HSCR (Hirschsprung Disease) sus-
ceptibility allele [4,5]. A single mutation allele T is
associated with 6-fold decrease in activity of the RET
gene enhancer. The homozygous variant T/T
increases the risk of Hirschprung disease 20-fold [5].
Variation in the frequency of allele T is observed in
the world. Scientific data shows that it is virtually* Correspondence: andp@man.poznan.pl
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reproduction in any medium, provided the orabsent within Africa, and has an intermediate fre-
quency in Europe (0.25), however it reaches high fre-
quency (0.45) in Asia [4,5].
The RET gene mutations, leading to the occurrence of
MTC, increasing the protein activity and variant T at
rs2435357 acts, in a sense, antagonistically to the RET
gene mutations, therefore it was interesting to investi-
gate the prevalence of this allele in our 48-person group
of patients with medullary thyroid carcinoma.
Methods
The group of 48 patients (37 men and 11 women)
with medullary thyroid carcinoma participating in the
study was not screened for mutations in the RET gene
and was selected on the basis of clinical symptoms. In
4 cases, a family history of medullary thyroid carcin-
oma (FMTC) was reported. The control group con-
sisted of 152 anonymous individuals (76 men and 76
women) randomly selected from the Polish population.
The analysis of alleles frequency at rs2435357 was per-
formed by using the PCR-RFLP method. In the first
stage, the RET gene fragment containing rs2435357
was amplified using forward primer 50gagtgcatgggga
cagtt30 and reverse primer 50ggaaactgccaattaggttat30.
Subsequently, the PCR product was subjected to re-
striction digestion with endonuclease Hin1II. The T allele
creates a restriction site for the enzyme. The digestion pro-
ducts were separated on 6% polyacrylamide gel and after-
wards DNA products were visualized with silver stainingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Restriction analysis of the fragment of RET gene for
the control group. Arrows indicates the digested RET+3:T allele.
The separation was performed on 6% polyacrylamide gel.











MTC patients 37 0 11 0
Control 68 8 66 10
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analysis was confirmed by sequencing (Figure 2). The stud-
ies was approved the local Ethics Committee at the Poznań
University of Medical Science, resolution No. 629/07.
Written informed consent was obtained from the patient
for publication of this report and any accompanying
images.
Results and discussion
For the Polish population, the incidence of heterozygous
variant rs2435357 reached almost 12% (18/152), while inFigure 2 Sequence analysis of the fragment of the RET gene encomp
Direct sequencing of PCR product performed using DYEnamic ET dye term
analyzed on MEGABACE 500 DNA sequencer (GE Healthcare).the study group of patients with MTC not even a single
T allele was found (Table 1). Frequency difference is
statistically significant and according to the Fisher’s
Exact Test the two-sided P value is 0.0080.
Mutation allele T is associated with reducing the
activity of the RET gene enhancer. The consequences
of this reduction have a negative impact on homozy-
gotes by increasing the risk of Hirschprung disease
several dozen times. The obtained results led to the
conclusion that possibly the presence of heterozygous
mutant allele T at rs2435357 can inhibit the develop-
ment of medullary thyroid carcinoma. This may be
related to the antagonistic effects of this polymorph-
ism in relation to the mutations that increase the
activity of the protein causing MTC. This conclusion
was drawn based only on a study of a small group of
patients with MTC and should be confirmed in a
larger cohort.
Taking our observation into consideration, it would be
interesting to investigate the possible role of the
rs2435357 in modifying the course of MEN2A.assing C/T polymorphism. Arrow indicates the polymorphic site.
inator (GE Healthcare). The sequencing reaction products were
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